NFKB1
NFKB1 is a gene that encodes the p105 precursor and its processed p50 subunit of the nuclear factor κB (NF-κB) transcription-factor family.
NFKB1 is a gene that encodes the p105 precursor and its processed p50 subunit of the nuclear factor κB (NF-κB) transcription-factor family. NF-κB1-derived proteins participate in regulatory complexes that control transcriptional programs involved in immune-cell activation, inflammatory response, cell survival, and apoptosis. Signaling initiated by receptors such as toll-like receptor 4 (TLR4), inflammatory cytokine receptors, and other innate-immune pathways can converge on NF-κB activity, thereby influencing expression of mediators including tumor necrosis factor-α (TNF-α), Interleukin-6 (IL-6), Interleukin-1β (IL-1β), and C-X-C motif chemokine ligand 8 (CXCL8).
In the publications summarized here, NFKB1 is principally examined as a molecular component or target of NF-κB signaling rather than as an isolated therapeutic target. Its reported contexts include neuroinflammation, macrophage reprogramming in cancer, inflammation associated with lipid metabolism, toxicant-induced tissue injury, ulcerative colitis, immune responses to vaccination, and immune–inflammatory mechanisms proposed in Alzheimer’s disease. Several studies evaluated NFKB1/NF-κB together with the NOD-like receptor NLRP3 inflammasome, oxidative stress pathways, apoptotic markers, or metabolic regulators.
Rebuilt from PubMed 10 Sept 2026 · no new papers today
Where the papers sit
8 papers study nfkb1 directly. Those 8 do not group into themes. NF-κB-linked inflammatory and immune mechanisms appear across brain-heart injury, metabolic and toxic disease, gut–brain disorders, cancer resistance, and vaccine response, but the topics do not converge on a shared direction. They are no more alike than papers drawn from anywhere in the corpus. 1 paradigm shift follows.
NFKB1 activity can support protective immune function rather than merely drive pathology
The colorectal-cancer peritoneal-metastasis study found that loss of SPP1 triggered NF-κB-driven macrophage reprogramming, relieved CD8+ T-cell suppression, and improved immunotherapy efficacy 42462726Jul; the BNT162b2 vaccine-response study in children with inborn errors of immunity found greater NFKB1 induction in memory B cells and peripheral T follicular helper cells among high responders, alongside stronger antibody-supporting programs 42027105Apr. Together, these findings challenge the assumption, reflected across the inflammatory and toxicology models, that NFKB1 activity is principally pathogenic and should be suppressed. They instead place NFKB1 in a context-dependent role in beneficial immune reprogramming and coordinated vaccine responses, making indiscriminate inhibition an inadequate therapeutic frame.
Recent Findings on NFKB1
Across these studies, NFKB1/NF-κB emerges as a central inflammatory node linking oxidative stress, apoptosis, cytokine production, and NLRP3-related signaling across gut–brain, reproductive, neurodegenerative, and intestinal disease models 42617470Aug42478942Jul42406869Jul42089391May. In diabetic mice, Faecalibacterium prausnitzii-derived short-chain fatty acids were associated with FFAR3/NF-κB/NLRP3 modulation, reduced neuroinflammation, and restored monoamine neurotransmitter levels, whereas nano-rosmarinic acid attenuated pesticide-induced testicular injury alongside reduced NF-κB/NLRP3 activation, oxidative stress, and apoptosis 42617470Aug42478942Jul. Network pharmacology similarly places NFKB1 among hub genes connecting gut microbiota-derived metabolites with Alzheimer disease-related immune-inflammatory, oxidative-stress, and apoptotic processes, but its docking results remain computational and require experimental validation 42406869Jul. In ulcerative colitis models, Shenling Baizhu Powder showed a broader multi-component effect involving NFKB1 and other inflammatory, survival, and apoptosis-related targets, indicating a shift toward integrated pathway and metabolomic investigation rather than single-target attribution 42089391May.
The two studies associate NFKB1-linked immune programs with markedly different outcomes, spanning therapeutic resistance in tumors and effective vaccine responses. In colorectal cancer peritoneal metastasis, SPP1+ cavity macrophages maintained an M2-like, lipid-dependent state that suppressed cytotoxic T-cell infiltration; SPP1 loss instead triggered NF-κB-driven macrophage reprogramming, while macrophage-specific SPP1 deletion or neutralization improved checkpoint blockade and adoptive T-cell efficacy 42462726Jul. Conversely, greater baseline NFKB1 expression in activated memory B cells and peripheral T follicular helper cells characterized individuals with inborn errors of immunity who mounted stronger antibody responses to BNT162b2 vaccination, alongside induction of other activation- and memory-associated genes 42027105Apr. Together, these findings point toward context-dependent use of NFKB1-related signatures: as a mechanistic lever for remodeling suppressive tumor macrophages and as a biomarker of immune readiness before vaccination.
Recent cardiac and metabolic work places NF-κB at the intersection of systemic inflammatory signaling and tissue metabolism. In stroke-exacerbated myocardial infarction, reduced APOM worsened cardiac injury by increasing Saa1-associated NF-κB activation, inflammasome-related signaling, cytokine release, lipid-droplet accumulation, and metabolite disturbances, supporting APOM as a potential protective target in brain–heart syndrome 42622732Aug. In a separate NAFLD model, Qiwei Gandanqing Granules reduced steatosis and inflammation while restoring carboxylesterase activity by disrupting antagonistic crosstalk between NF-κB-driven inflammation and PXR-mediated metabolism 42610928Aug. The direction of this work is therefore toward linking NF-κB activity to measurable metabolic and inflammatory states, with therapeutic assessment supported by proteomics, metabolic profiling, and in situ enzyme imaging.
Written from 8 PubMed abstracts, each one cited by PMID above. Published: 2026-08-22. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.